DRUG (DRUG)

Financial Metrics & Valuation Analysis

Enterprise Valuation (TTM)

Enterprise Value$700.83M
EV / Sales0.00
EV / EBITDA-22.38
EV / Operating Cash Flow-34.94
EV / Free Cash Flow-34.94

Return Metrics (TTM)

Return on Equity (ROE)-20.73%
Return on Assets (ROA)-8.83%
Return on Invested Capital (ROIC)-10.20%
Return on Capital Employed (ROCE)-10.21%

Yield Metrics

Earnings Yield-2.78%
Free Cash Flow Yield-1.99%

Balance Sheet Strength

Net Debt / EBITDA9.85
Current Ratio81.48
Working Capital$307.45M
Tangible Asset Value$307.52M
Net Current Asset Value$307.45M

Working Capital Efficiency

Days Sales Outstanding0.00
Days Payables Outstanding25030.06
Operating Cycle (Days)0.00
Cash Conversion Cycle-25030.06

Capital Allocation

CapEx / Revenue0.00%
CapEx / Operating Cash Flow-0.00%
R&D / Revenue0.00%
SG&A / Revenue0.00%

Fiscal Year 2025 Ratios

Audited annual results as of 2025-09-30

Margins

Gross Profit Margin0.00%
Operating Margin0.00%
Net Profit Margin0.00%

Solvency

Debt / Equity0.00
Quick Ratio36.10
Cash Ratio35.50

Per Share

Revenue / Share$0.00
FCF / Share-$1.26
PE Ratio-47.44